[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pomeranian Medical University Szczecin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":208},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,94,129,155,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100621440","long-acting-cabotegravir-and-rilpivirine-in-people-living-with-hiv-1-subtype-a6-a-real-world-retrospective-study-100621440",false,"NCT07370649","Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study","Long-Acting Cabotegravir And Rilipivirine In People Living With HIV-1 Subtype A6. A Multicentre Real-world, Retrospective Matched Case Study","LACRIS","Inclusion Criteria:\n\n* Confirmed diagnosis of HIV-1 infection\n* Age ≥18 years at the time of initiation of long-acting cabotegravir plus rilpivirine (CAB\u002FRPV LA)\n* Received at least one dose of CAB\u002FRPV LA as part of routine clinical care\n* Availability of relevant clinical data in medical records for retrospective analysis\n* Signed informed consent for use of clinical data\n* Agreement to provide an additional blood sample for proviral DNA genotyping, if HIV-1 subtype was unknown at treatment initiation\n\nExclusion Criteria:\n\n\\- Lack of patient consent for use of clinical data for research purposes","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","24 Months","OBSERVATIONAL","This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1. The focus is on individuals with HIV-1 subtype A6, which is common in Eastern Europe and among people who acquired HIV in that region, and on comparison with individuals with subtype B and those with an unknown subtype.\n\nAlthough long-acting cabotegravir and rilpivirine are widely used and effective, limited real-world data are available on how well this treatment works in people with HIV-1 subtype A6. This is important because subtype A6 has been suggested as a potential risk factor for treatment failure, but current evidence is inconclusive.\n\nThe study uses existing medical records from treatment centers in Poland, Germany, and the Czech Republic. It includes adults with HIV who have received at least one injection of long-acting cabotegravir and rilpivirine and follows their clinical outcomes for up to 24 months. Researchers will assess viral suppression, treatment persistence, adherence to injection schedules, and reasons for treatment discontinuation.\n\nThe results of this study will help clinicians better understand whether HIV-1 subtype A6 affects treatment outcomes and whether knowing a patient's HIV subtype is important when deciding to switch to long-acting injectable therapy. The findings may support safer and more effective use of this treatment in diverse patient populations.",[26,27,28,29],"Human Immunodeficiency Virus (HIV)-1 Infection","HIV-1 Subtype A6 Infection","HIV-1 Subtype B Infection","Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy",[31,32,33,34,35,36,37,38,39,40,41,42,43],"HIV-1","Long-Acting Antiretroviral Therapy","Cabotegravir","Rilpivirine","CAB\u002FRPV LA","HIV-1 Subtype A6","HIV-1 Subtype B","Virologic Suppression","Real-World Study","Retrospective Study","Injectable HIV Therapy","Treatment Persistence","Virologic Failure","RECRUITING","2026-06-09",{"date":47,"type":48},"2026-06-11","ACTUAL",{"date":50,"type":48},"2026-05-12",{"date":52,"type":21},"2027-03",{"name":54,"class":55},"Pomeranian Medical University Szczecin","OTHER",7,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":66,"conditions":67,"keywords":74,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100578269","home-monitoring-of-complete-blood-count-performed-by-patients---a-pilot-study-on-the-implementation-process-in-south-baltic-countries-100578269","NCT06809101","Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.","AMBeR eBlood","Inclusion Criteria:\n\n* legally competent patients\n* aged 18 or older\n* diagnosed with cancer (ICD-10: C00\\* - C97\\*)\n* enrolled at the Department of Oncology\u002FHematology for outpatients\n* participants who are willing and able to give informed consent for participation in the study\n* participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion\n\nExclusion Criteria:\n\n* inability to give informed consent due to mental capacity or language barrier\n* patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result\n* known bleeding disorder\n* bad circulation preventing the patient from getting enough blood drops to perform the test",{"count":65,"type":21},265,"Introduction:\n\nThe number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment. In case of poor blood results, the chemotherapy session must be omitted. For patients living far from the center, this means unnecessary travel with involvement of helpers, additional costs, increased potential of hospital acquired infections, and frustration associated with missed opportunity for treatment.\n\nAims:\n\nThe primary aim of this study is to gain knowledge about successful implementation of remote, home monitoring of complete blood count to cancer patients during and after systemic treatment for cancer. The secondary aim of the AMBeR collective study protocol is to pilot new technology, gain more context around future investigations and verify costs and changes in patient treatment pathways.\n\nMethodology:\n\nThe investigators will test implementation of home blood monitoring in three South Baltic Countries (DK, PL, GER). Each site will participate in the implementation study with study group á n=33 (total n=165) and control group n=20 (total n=100). The duration of the study is planned for 4 cycles of chemotherapy for each patient and a 3-month follow up period. The first cycle of learning and training at the Outpatient Daily Clinic, then the remaining 3 cycles of blood monitoring at home. The average cycle length is 21-30 days, number of measurements will be determined individually depending on the diagnosis. At a baseline, after 4 cycles of chemotherapy (12-16 weeks) and after a 3-month follow-up period, parallel studies will be carried out in both the study and control groups, using mixed methods the investigators will assess outcomes of reach, effectiveness, adoption, implementation and maintenance (RE-AIM).\n\nExpected benefits:\n\nImplementation of the AMBeR study should reduce the amount of unnecessary and nontherapeutic hospital visits and improve manageability and independence of the patients. The investigators believe that the decrease in the number of hospital visits will diminish the risk of infection for vulnerable individuals, as well as save costs for patients and hospitals. These factors will also translate into better logistics of chemotherapy units, decreased carbon-dioxide trail, and improved quality of life and patient empowerment.",[68,69,70,71,72,73],"Cancer","Cancer-related Problem\u002FCondition","Chemotherapy","Chemotherapy-induced Neutropenia","Chemotherapy Induced Anaemia","Chemotherapy Induced Thrombocytopenia",[75,76,77,78,79,80,81,82,83,84],"home blood monitoring","complete blood count","cancer","chemotherapy","implementation","research","e-health","oncology","home-based","feasibility","2026-02-26",{"date":87,"type":48},"2026-02-27",{"date":89,"type":48},"2025-03-17",{"date":91,"type":21},"2027-03-31",{"name":54,"class":55},5,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100620508","metabolic-obesity-in-normal-weight-monw-diagnostic-markers-stud-100620508","NCT07358533","Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud","Disorders Hidden Under the Guise of BMI - Metabolic Obesity in People With Normal Body Weight (MONW) - the Search for Diagnostic Markers and Its Consequences for Health","Inclusion Criteria:\n\n* Written, informed consent to participate in the research.\n* Gender: Female.\n* Age 18-35 years.\n* BMI in the range of 18.5-25 kg\u002Fm².\n\nExclusion Criteria:\n\n* Thyroid disease.\n* Pregnancy or breastfeeding.\n* Eating disorders.\n* Polycystic ovary syndrome (PCOS).\n* Hormone therapy and\u002For use of hormonal contraceptives.\n* Smoking.\n* Metal or silicone implants (contraindication for DXA\u002Fbody composition accuracy).\n* Vitamin and\u002For mineral supplementation.\n* Acute and\u002For chronic illnesses.\n* Type I or II diabetes, dyslipidemia, hypertension.\n* Use of hypolipemic, antihypertensive, antiglycemic, or insulin medications.",true,"FEMALE","35 Years",{"count":105,"type":21},176,"Metabolically Obese Normal Weight (MONW) represents a phenotype affecting individuals with a normal Body Mass Index (BMI) but characterized by excessive adipose tissue accumulation. This condition is associated with increased cardiovascular risk, insulin resistance, and endothelial dysfunction, yet remains underdiagnosed.\n\nThis observational longitudinal study aims to comprehensively evaluate the relationship between excessive adipose tissue deposition, endothelial dysfunction, and asprosin concentrations in young women. The study will recruit 176 healthy women aged 18-35 years with normal BMI (\\\u003C25 kg\u002Fm²). Participants will be divided into two groups based on body fat percentage (PBF) assessed by dual-energy X-ray absorptiometry (DXA): the MONW group (PBF ≥ 35.78%) and the Control group (PBF \\\u003C 35.78%).\n\nThe specific objectives of the study include:\n\n* Assessment of vascular endothelial function using flow-mediated dilation (FMD) of the brachial artery.\n* Evaluation of asprosin as a novel biomarker in the MONW phenotype.\n* Analysis of biochemical indices including asymmetric dimethylarginine (ADMA) and von Willebrand factor (vWF).\n* Advanced metabolomic profiling to identify metabolic signatures.\n\nParticipants will undergo anthropometric measurements, body composition analysis (DXA), and blood sampling for biochemical and hormonal analyses. The study aims to develop predictive models for early cardiovascular risk detection in normal-weight individuals.",[108,109,110],"Normal Weight Obesity","Metabolically Obese Normal Weight","Metabolic Syndrome",[112,113,114,115,116,117,118],"Endothelial Dysfunction","Metabolic Disorders","Visceral Adiposity","Flow-Mediated Dilation","Metabolomics","Asprosin","Normal Weight","NOT_YET_RECRUITING","2026-01-21",{"date":122,"type":48},"2026-01-23",{"date":124,"type":21},"2026-09",{"date":126,"type":21},"2029-09",{"name":54,"class":55},1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100618220","factors-influencing-cardiac-rehabilitation-success-100618220","NCT07328789","Factors Influencing Cardiac Rehabilitation Success","Assessment of the Effectiveness of Comprehensive Cardiac Rehabilitation and Identification of Factors Modulating Its Results","Inclusion Criteria:\n\n* Male patients aged 50-80 years\n* Hospitalization in the Cardiac Rehabilitation Ward\n* Undergone coronary artery bypass graft (CABG) surgery within the last 30 days\n* Written, informed consent to participate in the study\n\nExclusion Criteria:\n\n* Type II diabetes treated with insulin\n* Neuro-surgical operation in the last 6 months\n* Aneurysms of the cerebral arteries and aorta\n* Recurrent ischemic stroke (Cerebral Vascular Accident)\n* Presence of a pacemaker\n* Current treatment with testosterone","50 Years","80 Years",{"count":139,"type":21},150,"Cardiovascular diseases, especially after life-saving surgeries, require comprehensive cardiac rehabilitation (CR). We know that the effectiveness of CR varies among patients. The main goal of this study is to understand which factors-psychological, physical, cognitive, biochemical, and hormonal-influence the success and long-term durability of the recovery process. These findings will help us create more effective and personalized treatment programs.\n\nWho is Being Studied and What is Being Assessed? Study Group: 150 patients of both sexes, aged 50-80 years, hospitalized in the cardiac rehabilitation ward, primarily after Coronary Artery Bypass Grafting (CABG).\n\nStudy Period: Patients will be assessed at the start of their hospital stay, at the end of rehabilitation, and again 3-6 months after discharge.\n\nKey Assessment Areas (Modulating Factors)\n\nPhysical Status and Fitness:\n\nExercise tolerance (6-Minute Walk Test).\n\nMuscle strength (handgrip), balance, and gait.\n\nBody composition (analysis of muscle mass and fat tissue).\n\nRespiratory function and diaphragm mobility (ultrasound).\n\nPsychological and Cognitive Factors:\n\nAssessment of anxiety, depression, and general mental well-being.\n\nEvaluation of cognitive functions (memory, concentration) following cardiac surgery.\n\nSleep Problems (OSA):\n\nAssessment of the risk and severity of Obstructive Sleep Apnea (OSA), which is common in cardiac patients.\n\nAnalysis of OSA risk factors related to oral health (dentition, microbiome) and craniofacial structure.\n\nBiological Markers:\n\nHormonal tests (e.g., testosterone, estradiol) and their correlation with psycho-physical condition and the rehabilitation process.\n\nAnalysis of metabolic and muscle-related biomarkers (e.g., myokines: irisin, myostatin).",[142],"Rehabilitation",[144,145,146],"Cardiac Rehabilitation","Sex Hormones","Cognitive Dysfunction","2026-01-08",{"date":149,"type":48},"2026-01-09",{"date":151,"type":21},"2026-01-03",{"date":153,"type":21},"2029-07-01",{"name":54,"class":55},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":128},"100616657","enhanced-molecular-microbiological-surveillance-versus-ceftriaxone-prophylaxis-in-hematopoietic-cell-transplant-patients-100616657","NCT07308457","Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients","Comparison of Enhanced Molecular-Level Microbiological Surveillance and Ceftriaxone Prophylaxis in Patients Undergoing Hematopoietic Cell Transplantation: A Randomized, Prospective Medical Experiment","CRONOS","Inclusion Criteria:\n\n* Recipient of autologous or allogeneic hematopoietic stem cells from peripheral blood, bone marrow, or cord blood.\n* Age ≥18 years.\n* Ability to provide written informed consent.\n* No active infection for at least 2 weeks prior to transplantation.\n\nExclusion Criteria:\n\n* Controlled fungal infection.\n* Fever of unknown origin.\n* Ongoing antibiotic therapy (except cotrimoxazole).\n* Participation in any clinical study or experiment at the time of inclusion.",{"count":164,"type":21},100,"INTERVENTIONAL",[167],"NA","The goal of this clinical trial is to learn whether close microbiological monitoring without preventive antibiotics works as well as preventive treatment with ceftriaxone in adults receiving stem cell transplants. The study focuses on people with blood cancers or other conditions who need either autologous or allogeneic hematopoietic stem cell transplantation (HSCT).\n\nThe main questions the study aims to answer are:\n\nWhat percentage of participants develop an infection when they do not receive preventive antibiotics compared with those who receive daily ceftriaxone?\n\nDoes preventive ceftriaxone lower the chance of specific complications such as bloodstream infections, pneumonia, or severe sepsis?\n\nResearchers will compare two groups:\n\none group will not receive preventive antibiotics\n\none group will receive ceftriaxone once a day until their white blood cells recover or until signs of infection appear\n\nAll participants will:\n\nhave their body temperature monitored continuously starting one day before the transplant\n\nhave blood, urine, or other samples collected if they develop fever or symptoms of infection\n\nreceive standard medical care during and after the transplant\n\nstart standard antibiotic treatment if they develop signs of infection\n\nThis study will include 100 adults. The information collected will help determine whether skipping preventive antibiotics is safe in hospitals where bacteria often show resistance to commonly used drugs such as fluoroquinolones.",[170],"Incidence of Infectious Diseases",[172,173],"Hematopoietic Cell Transplantation","Bloodstream Infections","2025-12-19",{"date":176,"type":48},"2025-12-29",{"date":178,"type":48},"2024-09-01",{"date":180,"type":21},"2027-10-31",{"name":54,"class":55},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100563332","niraparib-maintenance-treatment-in-patients-with-newly-diagnosed-advanced-platinum--sensitive-oc-the-first-poland-rwe-study-100563332","NCT06614790","Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.","Patient Outcomes and Safety of Niraparib as Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, Ovarian Cancer. The First Real-World Evidence Study From Poland.","NIRAPARIB","Inclusion Criteria:\n\n1. Patients must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.\n2. Patients with a histologically confirmed diagnosis of nonmucinous high - grade epithelial ovarian cancer (serous, endometrial) that is stage III or IV according to the FIGO criteria.\n3. All patients with Stage IV disease are eligible. This includes those with inoperable disease, those who undergo PDS (R0 or macroscopic disease), or those for whom NACT is planned.\n4. Patients with Stage III are eligible if they meet the following criteria:\n\n   1. All FIGO III patients in spite of residual disease and cytoreductive surgery.\n   2. All patients with inoperable Stage III disease.\n   3. All Stage III patients after NACT chemotherapy.\n5. FFPE tumor tissue sample must be available for molecular analysis.\n6. Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 72 hours prior to receiving the first dose of study treatment.\n7. Patients must be postmenopausal, free from menses for \\>1 year, surgically sterilized, or willing to use highly effective contraception to prevent pregnancy (see 0) or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 180 days after the last dose of study treatment.\n\n   1. Serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance ≥60 mL\u002Fmin using the Cockcroft-Gault equation\n   2. Total bilirubin ≤1.5 × ULN or direct bilirubin ≤1.5 × ULN\n   3. AST and ALT ≤2.5 × ULN unless liver metastases are present, in which case they must be ≤5 × ULN\n8. Patients must have an ECOG score of 0 or 1.\n9. Patients must have normal BP or adequately treated and controlled hypertension.\n10. Patients must be able to take oral medication.\n\nExclusion Criteria:\n\n1. Patient has mucinous, germ cell, transitional cell, or undifferentiated tumor.\n2. Patient has low-grade or Grade 1 epithelial ovarian cancer.\n3. Patient has a known condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment in the opinion of the Investigator.\n4. Patient is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Patient is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use, during niraparib treatment and for 30 days after receiving the final dose of study treatment).\n5. Patient has any known history or current diagnosis of MDS or AML.\n6. Hypersensitivity to the active substance or to any of the excipients including tartrazine.\n7. Hypertension-Participants have systolic BP \\>140 mmHg or diastolic BP \\>90 mmHg that has not been adequately treated or controlled.\n8. Patients with prior history of PRES.",{"count":191,"type":21},300,"The study is observational, not interventional. The study will include patients with advanced ovarian cancer who have been treated in Poland based on a previous early access program, and who are currently being treated under the B.50 drug program, funded by the National Health Fund.\n\nOnly patients currently being treated in the B.50 program at 10 selected centers listed on this site may be included in the study.\n\nOf course, any patient in Poland eligible for maintenance treatment with niraparib can receive the drug, regardless of participation in this RWE study.The treatment involves administering niraparib as maintenance therapy for 3 years after the completion of chemotherapy, provided that the patient has responded to systemic treatment (NED, CR, PR).",[194],"Ovarian Cancer",[196,197,198],"maintenance treatment","iPARP","advanced ovarian cancer","2024-10-22",{"date":201,"type":48},"2024-10-23",{"date":203,"type":48},"2024-09-02",{"date":205,"type":21},"2026-01-07",{"name":54,"class":55},12,""]